RE-BVS – Piemonte Repository

Sfoglia per AUTORE
DE PROPRIS MS
Collezione AOU Novara

Items : 5

ZNF384 rearrangement is the most frequent genetic lesion in adult PH-negative and Ph-like-negative B-other acute lymphoblastic leukemia. Biological and clinical findings. in Leukemia & lymphoma / Leuk Lymphoma. 2023 Feb;64(2):483-486. doi: 10.1080/10428194.2022.2148217. Epub 2022 Dec 19.

2023
AOU Novara

Chiaretti S; Taherinasab A; Della Starza I; Canichella M; Ansuinelli M; De Propris MS; Messina M; Spinelli O; Santoro A; De Novi LA; Cardinali D; Schipani M; Arena V; Bassan R; Guarini A; Foà R;

High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study. in Haematologica / Haematologica. 2023 Aug 1;108(8):2091-2100. doi: 10.3324/haematol.2022.282116.

2023
AOU Alessandria
AO Cuneo
AO Ordine Mauriziano
AOU Città della Salute di Torino
AOU Novara

Foà R; Nanni M; Del Giudice I; Guarini A; Fazi P; Vignetti M; Piciocchi A; Cuneo A; Neri A; De Novi LA; De Propris MS; Pietrasanta D; Mattiello V; Visentin A; Vitale C; Albano F; Molinari MC; Liberati AM; Giordano A; Gottardi D; Galieni P; Patrizi VB; Tani M; Arcari A; Musuraca G; Deodato M; Massaia M; Rigolin GM; Scarfò L; et alii...

Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia. in Hematological oncology / Hematol Oncol. 2023 Aug;41(3):567-570. doi: 10.1002/hon.3080. Epub 2022 Oct 10.

2023
AOU Novara

Moia R; Dondolin R; De Propris MS; Talotta D; Mouhssine S; Perutelli F; Reda G; Mattiello V; Rigolin GM; Motta M; Olivieri J; Fanin R; Perbellini O; Ferrarini I; Mauro FR; Del Giudice I; Laurenti L; Tomasso A; Gentile M; Frustaci AM; Tedeschi A; Gozzetti A; Stelitano C; Visco C; Moreno C; Forconi F; Marasca R; Coscia M; Rossi D; et alii...

Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study. in Cancers / Cancers (Basel). 2021 Dec 31;14(1):207. doi: 10.3390/cancers14010207.

2021
AOU Alessandria
AO Ordine Mauriziano
AOU Città della Salute di Torino
AOU Novara

Piciocchi A; Cuneo A; Foà R; Rigolin GM; Fazi P; Neri A; Guarini A; Raponi S; Nanni M; De Propris MS; Della Starza I; Ibatici A; Murru R; Ruocco V; Del Giudice I; Varettoni M; Molinari A; Gentile M; Chiarenza A; Laurenti L; Gottardi D; Zinzani PL; Gozzetti A; Tani M; Musuraca G; Orsucci L; Re F; Di Renzo N; Liberati AM; et alii...

Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults. in The New England journal of medicine / N Engl J Med. 2020 Oct 22;383(17):1613-1623. doi: 10.1056/NEJMoa2016272.

2020
AOU Novara

Foà R; Bassan R; Vitale A; Elia L; Piciocchi A; Puzzolo MC; Canichella M; Viero P; Ferrara F; Lunghi M; Fabbiano F; Bonifacio M; Fracchiolla N; Di Bartolomeo P; Mancino A; De Propris MS; Vignetti M; Guarini A; Rambaldi A; Chiaretti S;